Neuroimmunology
Leptospirosis
Mar. 24, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
09.13.2023
Since the 1980s, we have known that neurologic soft signs can distinguish people with schizophrenia from psychiatrically healthy individuals. Neurologic soft signs are subtle neurological impairments that principally manifest as decreased sensory integration (trouble receiving and responding to information transmitted to the brain through the senses) and difficulties with balance, rapid successive movements, and right–left orientation.
Neurologic soft signs doesn't always cause impairment of daily living, but identifying them could improve the diagnosis and treatment of schizophrenia and enhance understanding of the disease itself. Unfortunately, barriers to assessment have persisted for more than 40 years—rating systems for neurologic soft signs are subjective, so it is difficult to reliably measure and compare deficits.
In a perspectives article published in Harvard Review of Psychiatry (HRP), part of the Lippincott portfolio from Wolters Kluwer, John Torous MD MBI and colleagues of Harvard's Beth Israel Deaconess Medical Center and the Massachusetts Mental Health Center in Boston, discuss how smartphone sensing technology could be used to create standardized neurologic soft sign assessments.
Advances in smartphones and digital phenotyping offer a means for more reliable scoring
In 2016, Dr. Torous and his colleagues were the first to define "digital phenotyping," the use of data from smart devices to identify behavior patterns that can detect disease. In the case of neurologic soft signs, physicians can collect information from a smartphone's motion sensors, like those that adjust the screen display from portrait to landscape and react to gaming-related gestures, to detect behavior patterns as possible neurologic soft sign markers. For example:
A test of balance: Patients stand with their arms held parallel to the floor and their eyes closed for one minute; patients could perform the same test with a smartphone attached to their sternums.
A test of motor coordination (like the tandem walk): Patients walk heel-to-toe in a straight line for 12 feet; the same test has been administered to patients with Parkinson disease by having them put a smartphone in their pants pockets.
A test of complex motor acts: Ask the patient to reproduce a series of audible taps; alternatively, the smartphone could play a beat with the patient tapping along, and the patient could be asked to continue tapping the same pattern after the beat stops.
Smartphones and digital phenotyping have multiple advantages over traditional assessment
A smartphone makes objective measurements so it can quantitatively evaluate how well a patient does on a test rather than have the examiner decide whether the patient is impaired. In addition, using smartphones for neurologic soft sign measurement could reduce the time necessary for neurological office visits since patients could complete aspects of the examination before or after a visit.
"Incorporating digital phenotyping into neurologic soft sign assessment offers the potential to make measurement more scalable, accessible, and directly comparable across locations, cultures, and demographics," Dr. Torous and his colleagues note. Some tests may require use of a camera, but with proper security and privacy features in place the data could be safely employed.
"The rapid adoption of telehealth measures due to the COVID-19 pandemic increased patient buy-in and enhanced privacy considerations, making it an advantageous time to introduce smartphone sensing technology and tools to measure neurologic soft signs," the authors conclude.
Source: News Release
Wolters Kluwer Health
September 12, 2023
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125